Cancer treatment: The combination of vaccination with other therapies

Cancer Immunology, Immunotherapy

Volumn 57, Issue 11, 2008, Pages 1735-1743

  Andersen, Mads Hald ^a   Sørensen, Rikke Bæk ^a   Schrama, David ^b   Svane, Inge Marie ^a   Becker, Jürgen C ^b   Thor Straten, Per ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Cancer; Chemotherapy; Combination; Conventional treatment; Vaccination

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CD137 ANTIBODY; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; MONOCLONAL ANTIBODY; NUCLEOSIDE; PD1 ANTIBODY; PROTEIN BCL 2; PROTEIN MCL 1; SURVIVIN; TUMOR VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL DEATH; COLON CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; ENDOTHELIUM CELL; IMMUNE SYSTEM; IMMUNOGENICITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; VACCINATION;

EID: 50649083704     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0480-y     Document Type: Conference Paper

References (84)

1. MH Andersen JC Becker P thor Straten 2005 Regulators of apoptosis: suitable targets for immune therapy of cancer Nat Rev Drug Discov 4 399 409
2. MH Andersen P Keikavoussi EB Bröcker B Schuler-Thurner M Jonassen I Søndergaard P thor Straten JC Becker E Kämpgen 2001 Induction of systemic CTL responses in melanoma patients after dendritic cell vaccination: correlation between disease progression and cessation of CTL responses Int J Cancer 61 820 824
3. MH Andersen P Kvistborg JC Becker P thor Straten 2005 Identification of an HLA-A1 restricted CTL epitope from Mcl-1 Leukemia 19 1084 1085
4. MH Andersen L Ostergaard Pedersen JC Becker P thor Straten 2001 Identification of a cytotoxic T lymphocyte response to the apoptose inhibitor protein survivin in cancer patients Cancer Res 61 869 872
5. MH Andersen S Reker JC Becker P thor Straten 2004 The melanoma inhibitor of apoptosis protein ML-IAP: a target for spontaneous cytotoxic T-cell responses J Invest Dermatol 122 392 399
6. MH Andersen S Reker P Kvistborg JC Becker P thor Straten 2005 Spontaneous immunity against Bcl-Xl in cancer patients J Immunol 175 2709 2714
7. MH Andersen RB Soerensen JC Becker P thor Straten 2006 HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer. J Transl Med 4 38
8. MH Andersen IM Svane P Kvistborg O Juul Nielsen E Balslev S Reker JC Becker P thor Straten 2005 Immunogenicity of Bcl-2 in cancer patients Blood 105 728 734
9. N Aptsiauri T Cabrera A Garcia-Lora MA Lopez-Nevot F Ruiz-Cabello F Garrido 2007 MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 256 139 189
10. C Berger MC Jensen PM Lansdorp M Gough C Elliott SR Riddell 2008 Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates J Clin Invest 118 294 305
11. M Bredel 2001 Anticancer drug resistance in primary human brain tumors Brain Res Brain Res Rev 35 161 204
12. CM Britten C Gouttefangeas MJ Welters G Pawelec S Koch C Ottensmeier A Mander S Walter A Paschen J Muller-Berghaus I Haas A Mackensen T Kollgaard P thor Straten M Schmitt K Giannopoulos R Maier H Veelken C Bertinetti A Konur C Huber S Stevanovic T Wolfel SH van der Burg 2007 The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays. Cancer Immunol Immunother 57 289 302 (E-pub ahead of print)
13. JE Celis JM Moreira I Gromova T Cabezon U Ralfkiaer P Guldberg P thor Straten H Mouridsen E Friis D Holm F Rank P Gromov 2005 Towards discovery-driven translational research in breast cancer FEBS J 272 2 15
14. A Chidgey J Dudakov N Seach R Boyd 2007 Impact of niche aging on thymic regeneration and immune reconstitution Semin Immunol 19 331 340
15. M Cobbold N Khan B Pourgheysari S Tauro D McDonald H Osman M Assenmacher L Billingham C Steward C Crawley E Olavarria J Goldman R Chakraverty P Mahendra C Craddock PA Moss 2005 Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers J Exp Med 202 379 386
16. MP Colombo S Piconese 2007 Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy Nat Rev Cancer 7 880 887
17. SP Cullen SJ Martin 2007 Mechanisms of granule-dependent killing Cell Death Differ 15 251 262
18. KE de Visser A Eichten LM Coussens 2006 Paradoxical roles of the immune system during cancer development Nat Rev Cancer 6 24 37
19. ML del Rio G Penuelas-Rivas R Dominguez-Perles P Ramirez P Parrilla JI Rodriguez-Barbosa 2005 Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation Eur J Immunol 35 3545 3560
20. S Dias SV Shmelkov G Lam S Rafii 2002 VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition Blood 99 2532 2540
21. G Dranoff 2005 CTLA-4 blockade: unveiling immune regulation J Clin Oncol 23 662 664
22. ME Dudley SA Rosenberg 2007 Adoptive cell transfer therapy Semin Oncol 34 524 531
23. AA Eggert MW Schreurs OC Boerman WJ Oyen AJ de Boer CJ Punt CG Figdor GJ Adema 1999 Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration Cancer Res 59 3340 3345
24. P Filipazzi R Valenti V Huber L Pilla P Canese M Iero C Castelli L Mariani G Parmiani L Rivoltini 2007 Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine J Clin Oncol 25 2546 2553
25. J Folkman 2007 Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 273 286
26. DI Gabrilovich 2007 Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited Lancet Oncol 8 2 3
27. DI Gabrilovich T Ishida S Nadaf JE Ohm DP Carbone 1999 Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function Clin Cancer Res 5 2963 2970
28. G Gallina L Dolcetti P Serafini SC De I Marigo MP Colombo G Basso F Brombacher I Borrello P Zanovello S Bicciato V Bronte 2006 Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells J Clin Invest 116 2777 2790
29. F Ghiringhelli C Menard PE Puig S Ladoire S Roux F Martin E Solary A Le Cesne L Zitvogel B Chauffert 2007 Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunol Immunother 56 641 648
30. D Grossman DC Altieri 2001 Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets Cancer Metastasis Rev 20 3 11
31. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70
32. H Helmbach E Rossmann MA Kern D Schadendorf 2001 Drug-resistance in human melanoma Int J Cancer 93 617 622
33. F Hillen AW Griffioen 2007 Tumour vascularization: sprouting angiogenesis and beyond Cancer Metastasis Rev 26 489 502
34. S Idenoue Y Hirohashi T Torigoe Y Sato Y Tamura H Hariu M Yamamoto T Kurotaki T Tsuruma H Asanuma T Kanaseki H Ikeda K Kashiwagi M Okazaki K Sasaki T Sato T Ohmura F Hata K Yamaguchi K Hirata N Sato 2005 A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins Clin Cancer Res 11 1474 1482
35. M Jaattela 2004 Multiple cell death pathways as regulators of tumour initiation and progression Oncogene 23 2746 2756
36. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Martin KW, Hoos A (2007) Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 57:303-315
37. H Kashkar JM Seeger A Hombach A Deggerich B Yazdanpanah O Utermohlen G Heimlich H Abken M Kronke 2006 XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack Blood 108 3434 3440
38. B Kavanagh A Ko A Venook K Margolin H Zeh M Lotze B Schillinger W Liu Y Lu P Mitsky M Schilling N Bercovici M Loudovaris R Guillermo SM Lee J Bender B Mills L Fong 2007 Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides J Immunother (1997) 30 762 772
39. P Lissoni F Malugani A Bonfanti R Bucovec S Secondino F Brivio A Ferrari-Bravo R Ferrante L Vigore F Rovelli M Mandala S Viviani L Fumagalli GS Gardani 2001 Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1 J Biol Regul Homeost Agents 15 140 144
40. MT Lotze HJ Zeh A Rubartelli LJ Sparvero AA Amoscato NR Washburn ME Devera X Liang M Tor T Billiar 2007 The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity Immunol Rev 220 60 81
41. B Maecker DH Sherr RH Vonderheide MS Bergwelt-Baildon N Hirano KS Anderson Z Xia MO Butler KW Wucherpfennig C O'Hara G Cole SS Kwak U Ramstedt AJ Tomlinson RM Chicz LM Nadler JL Schultze 2003 The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells Blood 102 3287 3294
42. M Matsuda M Petersson R Lenkei JL Taupin I Magnusson H Mellstedt P Anderson R Kiessling 1995 Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease Int J Cancer 61 765 772
43. MC McFadyen HL McLeod FC Jackson WT Melvin J Doehmer GI Murray 2001 Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance Biochem Pharmacol 62 207 212
44. A Meier S Reker IM Svane L Holten-Andersen JC Becker I Søndergaard MH Andersen P thor Straten 2005 Spontaneous CTL responses against peptides derived from the taxol resistance associated gene-3 (Trag-3) protein in cancer patients Cancer Immunol Immunother 54 219 228
45. V Monsurro FM Marincola 2007 Gene profiling for the prediction of tumor response to treatment: the case of immunotherapy. Adv Exp Med Biol 593 86 94
46. V Monsurro D Nagorsen E Wang M Provenzano ME Dudley SA Rosenberg FM Marincola 2002 Functional heterogeneity of vaccine-induced CD8(+) T cells J Immunol 168 5933 5942
47. V Monsurro E Wang MC Panelli D Nagorsen P Jin Z Katia K Smith Y Ngalame J Even FM Marincola 2003 Active-specific immunization against melanoma: is the problem at the receiving end? Semin Cancer Biol 13 473 480
48. V Monsurro E Wang Y Yamano SA Migueles MC Panelli K Smith D Nagorsen M Connors S Jacobson FM Marincola 2004 Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 104 1970 1978
49. RA Morgan ME Dudley JR Wunderlich MS Hughes JC Yang RM Sherry RE Royal SL Topalian US Kammula NP Restifo Z Zheng A Nahvi CR de Vries LJ Rogers-Freezer SA Mavroukakis SA Rosenberg 2006 Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 126 129
50. AG Niethammer R Xiang JC Becker H Wodrich U Pertl G Karsten TI Lemishka RA Reisfeld 2002 The vascular endothelial growth factor receptor 2: a self-antigen recognized by cytotoxic T cells mediating tumor-protective immunity Nat Med 8 1369 1375
51. RJ North 1982 Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells J Exp Med 155 1063 1074
52. M Obeid A Tesniere F Ghiringhelli GM Fimia L Apetoh JL Perfettini M Castedo G Mignot T Panaretakis N Casares D Metivier N Larochette EP Van F Ciccosanti M Piacentini L Zitvogel G Kroemer 2007 Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13 54 61
53. GA Ohnmacht FM Marincola 2000 Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma J Cell Physiol 182 332 338
54. K Otto MH Andersen AA Eggert P Keikavoussi L Ostergaard Pedersen JC Rath M Bock E Brocker P thor Straten E Kampgen JC Becker 2004 Therapy-induced T cell responses against the universal tumor antigen survivin Vaccine 23 884 889
55. G Parmiani C Castelli P Dalerba R Mortarini L Rivoltini FM Marincola A Anichini 2002 Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 94 805 818
56. G Pawelec S Heinzel R Kiessling L Muller Q Ouyang J Zeuthen 2000 Escape mechanisms in tumor immunity: a year 2000 update Crit Rev Oncog 11 97 133
57. AP Rapoport EA Stadtmauer N Aqui A Badros J Cotte L Chrisley E Veloso Z Zheng S Westphal R Mair N Chi B Ratterree MF Pochran S Natt J Hinkle C Sickles A Sohal K Ruehle C Lynch L Zhang DL Porter S Luger C Guo HB Fang W Blackwelder K Hankey D Mann R Edelman C Frasch BL Levine A Cross CH June 2005 Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer Nat Med 11 1230 1237
58. B Rochat JM Morsman GI Murray WD Figg HL McLeod 2001 Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296 537 541
59. M Ropke J Hald P Guldberg J Zeuthen L Norgaard L Fugger A Svejgaard SH van der Burg HW Nijman CJM Melief M-H Claesson 1996 Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide Proc Natl Acad Sci USA 93 14704 14707
60. S Sakaguchi 2005 Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self Nat Immunol 6 345 352
61. F Sallusto J Geginat A Lanzavecchia 2004 Central memory and effector memory T cell subsets: function, generation, and maintenance Annu Rev Immunol 22 745 763
62. F Sallusto CR Mackay 2004 Chemoattractants and their receptors in homeostasis and inflammation Curr Opin Immunol 16 724 731
63. H Schmidt S Suciu CJ Punt M Gore W Kruit P Patel D Lienard H von der Maase AM Eggermont U Keilholz 2007 Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial J Clin Oncol 25 1562 1569
64. M Schmitz P Diestelkoetter B Weigle F Schmachtenberg S Stevanovic D Ockert HG Rammensee EP Rieber 2000 Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides Cancer Res 60 4845 4849
65. JL Schultze RH Vonderheide 2001 From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens Trends Immunol 22 516 523
66. TN Schumacher 2002 T-cell-receptor gene therapy Nat Rev Immunol 2 512 519
67. B Seliger U Ritz S Ferrone 2006 Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation Int J Cancer 118 129 138
68. S Shangary DE Johnson 2003 Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family Leukemia 17 1470 1481
69. CL Slingluff Jr AL Cox RA Henderson DF Hunt VH Engelhard 1993 Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes J Immunol 150 2955 2963
70. CL Slingluff Jr DE Speiser 2005 Progress and controversies in developing cancer vaccines J Transl Med 3 18
71. N Sommerfeldt P Beckhove Y Ge F Schutz C Choi M Bucur C Domschke C Sohn A Schneeweis J Rom D Pollmann D Leucht I Vlodavsky V Schirrmacher 2006 Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes Cancer Res 66 7716 7723
72. K Tanaka S Iwamoto G Gon T Nohara M Iwamoto N Tanigawa 2000 Expression of survivin and its relationship to loss of apoptosis in breast carcinomas Clin Cancer Res 6 127 134
73. T Tsuruma F Hata T Torigoe T Furuhata S Idenoue T Kurotaki M Yamamoto A Yagihashi T Ohmura K Yamaguchi T Katsuramaki T Yasoshima K Sasaki Y Mizushima H Minamida H Kimura M Akiyama Y Hirohashi H Asanuma Y Tamura K Shimozawa N Sato K Hirata 2004 Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer J Transl Med 2 19
74. RH Vonderheide WC Hahn JL Schultze LM Nadler 1999 The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes Immunity 10 673 679
75. M Vukmanovic-Stejic Y Zhang JE Cook JM Fletcher A McQuaid JE Masters MH Rustin LS Taams PC Beverley DC Macallan AN Akbar 2006 Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo J Clin Invest 116 2423 2433
76. V Wacheck E Selzer P Gunsberg T Lucas H Meyer C Thallinger BP Monia B Jansen 2003 Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells Br J Cancer 89 1352 1357
77. S Wang D Yang ME Lippman 2003 Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists Semin Oncol 30 133 142
78. HG Wendel SW Lowe 2004 Reversing drug resistance in vivo Cell Cycle 3 847 849
79. TL Whiteside 1999 Signaling defects in T lymphocytes of patients with malignancy (see comments) Cancer Immunol Immunother 48 346 352
80. K Wing Z Fehervari S Sakaguchi 2006 Emerging possibilities in the development and function of regulatory T cells Int Immunol 18 991 1000
81. R Xiang N Mizutani Y Luo C Chiodoni H Zhou M Mizutani Y Ba JC Becker RA Reisfeld 2005 A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication Cancer Res 65 553 561
82. A Yamada K Kawano M Koga T Matsumoto K Itoh 2001 Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes Cancer Res 61 6459 6466
83. B Zhang CH Maris J Foell J Whitmire L Niu J Song BS Kwon AT Vella R Ahmed J Jacob RS Mittler 2007 Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent J Clin Invest 117 3029 3041
84. H Zhou Y Luo M Mizutani N Mizutani RA Reisfeld R Xiang 2005 T cell-mediated suppression of angiogenesis results in tumor protective immunity Blood 106 2026 2032